Literature DB >> 18189189

Differential CCR5Delta32 allelic frequencies in juvenile idiopathic arthritis subtypes: evidence for different regulatory roles of CCR5 in rheumatological diseases.

I Scheibel1, T Veit, A G Neves, L Souza, S Prezzi, S Machado, C Kohem, M Icarelli, R Xavier, J C Brenol, J A B Chies.   

Abstract

BACKGROUND: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease of childhood and is characterized by persistent arthritis for at least 6 weeks. Its aetiopathogenesis is unknown but there is strong evidence that there is a substantial genetic component. Chemokine receptors genes are among the candidate genes for association with arthritis and other inflammatory diseases. The CC chemokine receptor 5 (CCR5)Delta32 polymorphism has been associated with rheumatoid arthritis (RA), conferring a protective effect.
OBJECTIVE: To determine whether the CCR5Delta32 polymorphism is associated with JIA and RA in Brazilian patients.
METHODS: We investigated 203 RA patients, 101 JIA patients, and 104 healthy individuals by amplification of the CCR5Delta32 deletion. We compared the allelic frequencies among these groups, as well as among different JIA subtypes.
RESULTS: The frequency of the Delta32 allele was higher in JIA patients (9.4%) as compared to control subjects (3.8%) and RA patients (3.2%). Grouping the patients according to JIA subtypes, we observed a higher CCR5Delta32 allelic frequency in the subtypes with a greater inflammatory component: 4.1% in oligoarticular (n = 49), 11.2% in polyarticular (n = 40) [9.5% in rheumatoid factor negative (RF-) and 33.3% in RF positive (+)], and 25% in systemic JIA (n = 12).
CONCLUSIONS: This study suggests that in JIA, unlike in RA, CCR5Delta32 does not have a protective effect, but instead it could be a factor associated with more inflammatory forms of the disease. These observations give rise to new questions about the mechanism and the cellular types involved in JIA as well as about the aetiology of JIA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18189189     DOI: 10.1080/03009740701631935

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  13 in total

1.  Functional CCR5 receptor protects patients with arthritis from high synovial burden of infecting Chlamydia trachomatis.

Authors:  Hervé C Gérard; Jessica A Stanich; Cynthia E Oszust; Judith A Whittum-Hudson; John D Carter; H Ralph Schumacher; Alan P Hudson
Journal:  Am J Med Sci       Date:  2010-12       Impact factor: 2.378

2.  CCR5Δ32 (rs333) polymorphism is associated with the susceptibility to systemic lupus erythematosus in female Brazilian patients.

Authors:  Thiago Hissnauer Leal Baltus; Ana Paula Kallaur; Marcell Alysson Batisti Lozovoy; Helena Kaminami Morimoto; Francieli Delongui; Daniela Frizon Alfieri; Tatiane Mayumi Veiga Iriyoda; Isaias Dichi; Andrea Name Colado Simão; Edna Maria Vissoci Reiche
Journal:  Rheumatol Int       Date:  2015-06-14       Impact factor: 2.631

Review 3.  [Genetic background of juvenile idiopathic arthritis].

Authors:  J P Haas
Journal:  Z Rheumatol       Date:  2010-08       Impact factor: 1.372

4.  Lack of association between beta 2-adrenergic receptor polymorphisms and juvenile idiopathic arthritis.

Authors:  G Pont-Kingdon; J Bohnsack; K Sumner; A Whiting; B Clifford; S S Guthery; L B Jorde; E Lyon; S Prahalad
Journal:  Scand J Rheumatol       Date:  2009 Mar-Apr       Impact factor: 3.641

5.  Association of the CCR5 gene with juvenile idiopathic arthritis.

Authors:  A Hinks; P Martin; E Flynn; S Eyre; J Packham; A Barton; J Worthington; W Thomson
Journal:  Genes Immun       Date:  2010-05-13       Impact factor: 2.676

6.  Considerations About the Role of the CCR5 Gene in Juvenile Idiopathic Arthritis - Look at the Whole or Put All Parts Together?

Authors:  Tiago Degani Veit; Ilóite Scheibel; José Artur B Chies
Journal:  Open Rheumatol J       Date:  2011-11-29

7.  IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukin-1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis.

Authors:  Victoria L Arthur; Emily Shuldiner; Elaine F Remmers; Anne Hinks; Alexei A Grom; Dirk Foell; Alberto Martini; Marco Gattorno; Seza Özen; Sampath Prahalad; Andrew S Zeft; John F Bohnsack; Norman T Ilowite; Elizabeth D Mellins; Ricardo Russo; Claudio Len; Sheila Oliveira; Rae S M Yeung; Alan M Rosenberg; Lucy R Wedderburn; Jordi Anton; Johannes-Peter Haas; Angela Rösen-Wolff; Kirsten Minden; Ann Marie Szymanski; Wendy Thomson; Daniel L Kastner; Patricia Woo; Michael J Ombrello
Journal:  Arthritis Rheumatol       Date:  2018-06-28       Impact factor: 10.995

8.  A comprehensive review of the genetics of juvenile idiopathic arthritis.

Authors:  Sampath Prahalad; David N Glass
Journal:  Pediatr Rheumatol Online J       Date:  2008-07-21       Impact factor: 3.054

Review 9.  C-C chemokine receptor type five (CCR5): An emerging target for the control of HIV infection.

Authors:  Fatima Barmania; Michael S Pepper
Journal:  Appl Transl Genom       Date:  2013-05-26

10.  Comparison of the editing patterns and editing efficiencies of TALEN and CRISPR-Cas9 when targeting the human CCR5 gene.

Authors:  Arildo Nerys-Junior; Luciene P Braga-Dias; Paula Pezzuto; Vinícius Cotta-de-Almeida; Amilcar Tanuri
Journal:  Genet Mol Biol       Date:  2018-03-19       Impact factor: 1.771

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.